The approval of a new drug by the FDA has initiated a critical decision-making process for health plans regarding its coverage. This decision could lead to a lengthy evaluation involving six to seven specialists over a period of two to three months, accumulating costs that may reach approximately $100,000 by the time the process is completed.
In the meantime, patients await treatment, facing significant risks. Delays in administering medications for conditions like schizophrenia can result in hospitalizations, which cost health plans between $8,000 and $15,000 per admission. If several hundred patients are affected, this could lead to unnecessary expenditures of up to $7 million for a single health plan.
The current healthcare landscape reveals a broader issue: while expertise exists, timely access to the right specialists remains a challenge. This problem has parallels in enterprise technology, where AI implementations often fail to deliver measurable benefits due to poorly integrated processes. Analysts predict a significant number of AI projects will be discontinued by 2027, primarily due to insufficient risk management and unclear value propositions.